Beyond Avoidance: Rethinking Food Allergy Treatment

How Dr. Tina Sindher’s research at Stanford is transforming prevention, diagnosis, and daily life for allergic families

Approximately 8–10% of people in the United States live with food allergies — nearly 35 million individuals whose daily lives are shaped by constant vigilance, sudden symptoms after accidental exposure, and, in severe cases, life-threatening reactions. Each year, around 175 deaths are attributed to food-related allergic reactions. Beyond the physical danger, however, the psychological burden is immense: children must remain constantly alert in classrooms and social settings, while parents and adults often experience chronic stress and anxiety. At Stanford University, pediatric allergist Dr. Tina Sindher is working to transform this reality. Her research moves beyond simply confirming allergies and instead builds a comprehensive system of prevention, diagnosis, and treatment aimed at helping “allergic families” reclaim a normal life.

Historically, allergy treatment and diagnosis have been limited. Skin prick tests and blood IgE testing can confirm sensitization, but they often fail to predict severity and carry high false-positive rates. Clinical oral food challenges, considered the gold standard, require patients to ingest allergens under medical supervision — a time-consuming process that carries real risk. Moreover, traditional management strategies focus primarily on avoidance, which cannot fully protect patients from accidental exposure and does little to reduce underlying sensitivity.

Dr. Sindher’s research addresses these limitations from multiple angles. In prevention studies, her team works with 2-month-old infants with severe eczema, a condition strongly associated with early food allergy development. They hypothesize that aggressive treatment of eczema and minimizing early skin damage may reduce the risk of later allergic sensitization. This approach reflects a broader shift in medicine: intervene earlier to alter the trajectory of disease.

In diagnosis, the team is investigating reliable biomarkers that can be identified through blood samples. By discovering measurable indicators that correlate with true allergy risk and severity, physicians could move beyond trial-and-error testing toward faster, more accurate, and safer evaluation methods.

On the treatment front, clinical trials have highlighted the effectiveness of omalizumab, a medication administered by injection that reduces allergic reaction risk by targeting IgE antibodies. In addition, researchers are exploring sublingual immunotherapy, which places small amounts of allergen under the tongue with relatively mild side effects, and a peanut patch designed to deliver controlled exposure through the skin — an especially appealing option for children who fear injections.

The impact of these advances is not merely clinical but deeply personal. After several weeks in trials, patients reported experiences that once felt impossible: “I went to an ice cream shop with my friend for the first time and I wasn’t worried,” one shared. Another family said, “We traveled out of the country to visit relatives because it finally felt safe for our food-allergic child.” These stories illustrate that the goal of allergy research is not simply avoidance of reactions, but restoration of normalcy.

Although treatments like omalizumab still require injections, they significantly reduce the constant fear that defines life with severe allergies. By combining prevention, improved diagnosis, and innovative therapies, Dr. Sindher’s work represents a shift from survival toward freedom, giving families not just protection but peace of mind.

Writer: [Maxim Bian] | Editor: [Enyi Guan]

This article is based on Stanford Report — “Living with food allergy has a bigger quality-of-life toll than we realize.”